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Adhesion molecule polymorphisms and the development of in graft survival thereafter remains unchanged because
chronic renal allograft failure. of CAF. The pathophysiology of the condition is not
Background. Chronic allograft failure (CAF) is a major well defined but involves graft injury by both alloantigen-cause of late graft loss in renal transplantation. Up-regulation
dependent and alloantigen-independent mechanisms.of adhesion molecules has been demonstrated in renal allograft
Clinically, it has been defined by the Alexis Carrel Con-biopsies during both acute and chronic rejection, and these
molecules are known to regulate leukocyte migration into the ferences as an insidious process characterized by a slow,
graft. progressive decline in graft function more than three
Methods. A single-center retrospective study was performed months after transplantation, which is associated withbetween 1985 and 1996 on renal transplant recipients who devel-
the development of proteinuria and hypertension. Theoped CAF. Genotyping was performed for five polymorphisms
diagnosis can be confirmed by histological assessment ofin intercellular adhesion molecule-1 (ICAM-1), E-selectin, and
L-selectin. Frequency data for the polymorphisms in the CAF transplant core biopsies, which typically show tubular
group (N 5 62) and their matched donors, where available atrophy, glomerulosclerosis, interstitial fibrosis, and arte-
(N 5 33), were compared with a group of recipients with graft
riosclerosis in the absence of recurrent disease [2, 3].survival of more than 10 years (N 5 110) and a group of United
The early stages of CAF can be studied in detail inKingdom (UK) controls (N 5 101).
Results. A variant allele in exon 4 of ICAM-1 (R241) was animal models of organ transplantation. Early up-regula-
more common in the CAF recipients compared with both long- tion of adhesion molecules is observed, followed by infil-
term survivors and UK controls (19.4 vs. 10.0 and 9.4%, P 5 tration of the graft with leukocytes and macrophages
0.015 and 0.025). In addition, stratification by time to graft
and the development of progressive fibrosis [4]. In hu-failure caused by CAF revealed more rapid failure in the pres-
mans, the correlation with the degree of interstitial fi-ence of another ICAM-1 variant in the recipient (E469) in
exon 6 (P 5 0.033). brosis at six months and the development of CAF is
Conclusions. ICAM-1 polymorphisms may represent a pre- consistent with the animal models [5]. Currently, there
determined genetic risk factor for CAF. The polymorphism in is no effective treatment for clinically established CAF,exon 4 is in the Mac-1 binding site, and that in exon 6 is in
and future therapies need to be directed at the earlythe fifth immunoglobulin-like domain. Potential mechanisms
events in the post-transplant course. Adhesion moleculesof action of ICAM-1 variants in CAF include an alteration of
activity as an adhesion molecule, altered costimulation, or a therefore represent an attractive target for investigation
minor histocompatibility antigen. with a view to intervention in CAF.
Leukocyte adhesion molecules play a key role in leuko-
cyte migration to sites of inflammation, as well as in co-
Chronic allograft failure (CAF) is the major cause of stimulation of the immune response. We have studied five
transplant failure after the first year [1], and although polymorphisms in three adhesion molecules, as they are
graft survival at one year in the cyclosporine era is supe- involved at distinct stages in the host response. E-selectin
rior to that in the azathioprine era, the rate of decline (CD62E) and L-selectin (CD62L) are involved at the
stage of leukocyte rolling and tethering to the vascular
endothelium. L-selectin is constitutively expressed onKey words: transplantation, polymorphism, R241, E469, genetic risk
factor, ICAM-1. leukocytes, whereas E-selectin is expressed on only acti-
vated endothelium. Intercellular adhesion molecule-1Received for publication August 4, 1998
(ICAM-1, CD54) in the normal kidney is expressed atand in revised form December 11, 1998
Accepted for publication December 14, 1998 high levels on endothelial cells and interacts with the b2
integrins Mac-1 and LFA-1. ICAM-1 is involved in leuko- 1999 by the International Society of Nephrology
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cyte adhesion [6], and in addition, it enhances T helper In brief, PCR was carried out in a final volume of 23
ml in 96-well plates under conditions identical to thosecell activation [7]. Up-regulation of adhesion molecule
expression has been demonstrated in allografts after is- described for HLA phototyping [19]. The final concen-
trations of the reaction components were as follows: 200chemia-reperfusion injury [8] and during both acute and
chronic rejection [9–13]. mm of each dNTP (primers as specified in Table 1), 2
mm MgCl2, 67 mm Tris base, pH 8.8, 16.6 mm ammoniumSeveral polymorphisms have been identified in the
genes encoding adhesion molecules, including ICAM-1, sulfate, 0.01% (vol/vol) Tween 20, between 0.01 and 0.1
mg DNA, and 0.2 units of Taq polymerase (AdvancedE-selectin, and L-selectin [14–16]. Although a clear func-
tional effect of these polymorphisms has yet to be de- Biotechnology, London, UK) Each plate was centrifuged
briefly (15 sec at 300 rpm) before being placed into afined, this genetic variability may influence susceptibility
to disease. An association between a polymorphism in PCR machine.
Polymerase chain reaction amplifications were carriedICAM exon 4 and both ulcerative colitis and Crohn’s
disease has already been described [17], as has suscepti- out in MJ Research 96 V machines under the following
cycling conditions: one minute at 968C; five cycles of 25bility to cerebral malaria [18]. To our knowledge, no
controlled studies have been published examining candi- seconds at 968C, 45 seconds at 708C, 45 seconds at 728C;
21 cycles of 25 seconds at 968C, 50 seconds at 658C, anddate gene polymorphisms in CAF.
We developed the hypothesis that polymorphic vari- 45 seconds at 728C; four cycles of 25 seconds at 968C, 60
seconds at 558C, and 120 seconds at 728C. An aliquotants in adhesion molecules may have differing function
in terms of leukocyte adhesion, migration, and/or costim- (20 ml) of the PCR reaction of 23 ml plus 10 ml loading dye
was loaded into a 1% agarose gel (containing ethidiumulation. This might result in varying genetic susceptibility
to graft damage during the initial ischemia-reperfusion bromide) in 0.5 3 Tris-Borate EDTA solution (TBE).
Gels were electrophoresed for 30 minutes at 200 V/cm2.injury and the subsequent alloimmune response and,
therefore, to the development and progression of CAF. Gels were photographed (black and white) under ultravi-
olet light (320 nm).
The specificity of each reaction is listed in Table 1,METHODS
and each gel was scored for the presence or absence of an
A retrospective review was performed of all renal allele-specific band, provided that a control amplification
transplants performed at the Oxford Transplant Center band was present.
between 1985 and 1996. The total number of transplants Statistical analysis was performed using SPSS (SPSS
performed during this period was 862. A total of 71 Inc., version 7.1). Comparisons were made using a Fisher
recipients who fulfilled the clinical/biopsy criteria of exact test between CAF patients and their matched do-
CAF established by the Alexis Carrel conferences was nors (where available) and the two control groups. The
identified [2, 3]. DNA was available for study from 62 of two randomly assigned CAF groups were initially ana-
these (87.3%). Controls used were 101 United Kingdom lyzed separately, and the results presented here are for
transplant donors, which have been shown previously to only those factors that were significant in both data sets.
be representative of the United Kingdom population in Survival plots of time to graft failure from CAF were
HLA genotyping reports [19], and 110 renal transplant produced for E469 E/K and were compared using the
recipients with grafts surviving more than 10 years. The log-rank test.
CAF recipients were divided into two groups (N 5 31)
at random prior to genotyping. Renal transplant donors
RESULTSfor the CAF group were genotyped subject to DNA
availability (N 5 33); five of these donors overlapped Polymorphisms in E-selectin and L-selectin were ob-
served at the same frequencies in the study group andwith those from the donor control group.
DNA extraction was carried out using a salting-out both control populations (Table 2). An increased fre-
quency was observed for the ICAM R241 allele. Theprocedure. Genotyping was performed using a polymer-
ase chain reaction (PCR) sequence-specific method un- phenotype containing this allele was more common in
the CAF recipients compared with both UK controlsder conditions that we have previously described for
HLA typing [20]. Primers were designed with appro- and long-term recipients (35 vs. 18 and 19%, P 5 0.015
and P 5 0.025, respectively). Considering the individualpriate mismatches to detect the five polymorphisms stud-
ied. The primers used and their specificities are shown allele frequencies, a similar pattern was seen (Table 2),
with the ICAM R241 allele being more frequent in CAFin Table 1. The control primers used were specific for
either a constant region of HLA DRB1 (796 base prod- recipients compared with UK controls and long-term
recipients (19.4 vs. 9.4 and 10.0%, P 5 0.012 and P 5uct) or a region of the human growth hormone (size 927
bases) and were chosen on the basis of the size of the 0.033, respectively). Further analysis of the results found
that the ICAM R241 allele was also more common inpredicted amplicon.
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Table 1. Primers used for detection of polymorphisms in the adhesion molecules L-selectin, E-selectin and ICAM-1
Polymorphism Primer no. Primer sequence Specificity
L-selectin aa 206 F/L 904 59TATGGGCCCCAGTGTCAGT aa 206 F
905 59ATGGGCCCCAGTGTCAGC aa 206 L
906 59CAAGCTCATTAGATCGTGAGC common
E-selectin aa 128 S/R 907 59CTGTACCAATACATCCTGCA aa 128 S
908 59CTGTACCAATACATCCTGCC aa 128 R
909 59TCTGACTTCATAGTCTCAGCT common
aa 554 L/F 910 59TCCTGACATTAGCACCATTTC aa 554 L
911 59TCCTGACATTAGCACCATTTT aa 554 F
912 59CCACACTGAGTTGTACTACTA common
ICAM-1 aa 241 G/R 854 59GTGGTCTGTTCCCTGGACG aa 241 G
855 59GTGGTCTGTTCCCTGGACA aa 241 R
aa 469 E/K 856 59GCACATTCACGGTCACCTC aa 469 E
857 59GTGGTCTGTTCCCTGGACA aa 469 K




For each of the sequence specific reactions a common “consensus” primer is combined with the specific primer.
Table 2. Frequencies of adhesion molecule polymorphisms adhesion molecules on the time to graft loss from CAF.
in study group and controls
Stratification of the group of CAF recipients by time to
Chronic Long-term graft failure revealed that more rapid failure occurred
failure CAF donors survivors UK controls in the presence of the ICAM E469 variant in the recipi-Polymorphism (N 5 62) (N 5 33) (N 5 110) (N 5 101)
ent. The numbers available for this survival analysis were
L-selectin
relatively small; thus, the result, although significant us-F206 92 (74.2) 48 (72.7) 158 (71.8) 154 (76.2)
L206 32 (25.8) 18 (27.3) 62 (23.8) 48 (23.8) ing the log-rank test (P 5 0.033), should be interpreted
E-selectin with caution. This is illustrated in the Kaplan–Meier
S128 112 (90.3) 59 (89.4) 190 (86.4) 177 (87.6)
survival plots shown in Figure 1.R128 12 (9.7) 7 (10.6) 30 (13.6) 25 (12.4)
L554 124 (100) 65 (98.5) 220 (100) 200 (99)
F554 0 (0) 1 (1.5) 0 (0) 2 (1)
ICAM-1 DISCUSSION
G241 100 (80.6) 53 (82.8) 198 (90.0) 183 (90.6)
The optimum approach to analysis of genetic factorsR241 24 (19.4)a 11 (17.2) 22 (10.0) 19 (9.4)
E469 56 (45.2) 29 (45.3) 88 (40.0) 95 (47) involved in disease susceptibility involves the use of fami-
K469 68 (54.8) 35 (54.7) 132 (60.0) 107 (53) lies. Such a study is clearly not possible with respect to
Numbers represent allele frequencies, the percentage is given in parentheses. CAF, owing to a low population incidence, that is, be-
a P , 0.05 vs. long-term survivors and UK controls
cause it occurs in a restricted subset of transplant patients
and a lack of suitable families exists. This led us to use
an association study. To overcome a major problem of
association studies, that is, association by chance, weCAF donors than either control group, as it was present
used a two-set approach to the analysis of our data. Wein 31%, although this result did not reach statistical sig-
only considered a difference to be significant if presentnificance.
in both data sets. In addition, we used two distinct controlOne possibility was that the R241 allele was acting as a
groups: one of UK controls, with no renal disease, andminor histocompatibility antigen. We therefore analyzed
a second of recipients with long-term renal allografts inthe degree of matching at ICAM 241 for the CAF group
order to control for associations with renal disease per se.and their available donors. It was found that there were
Our results demonstrate an effect on the incidence offive mismatches from 32 pairs in which R241 was present
CAF for the 241G/R polymorphism in exon 4 of ICAM-1in the donor and not in the recipient, suggesting that
with an increased risk associated with the variant allelemismatching was not a significant effect. The R241 allele
(R241) that occurs in 10% of the control population. Inoccurs as a heterozygote and only very rarely (less than
addition, we have demonstrated an effect on the rate of0.01%) as a homozygote; thus, we were unable to test
development of CAF, which occurs more rapidly post-the possibility that recipients of an R241 homozygote
transplant in the presence of the variant allele (469K)genotype were more likely to develop CAF.
in ICAM-1 exon 6.Chronic allograft failure may occur relatively early
The allele frequencies in each group were similar forafter transplantation, although this is not the case in
all allografts. We sought to analyze a possible effect of both E-selectin and L-selectin. There were no significant
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to a high affinity, more active state [24]. It is possible
that binding with a variant ligand would not effect such
a change in affinity and would therefore have a function-
ally different effect. The 469 E/K polymorphism is in exon
6 and results in a transition from glutamic acid to lysine in
the fifth immunoglobulin-like domain of ICAM-1. This
polymorphic variant has not been well studied but has
been shown to be involved with adhesion of B cells and
follicular dendritic cells [25]. The amino acid change is
a significant one and would be expected to have an effect
on binding, but more studies are required to prove that
hypothesis.
As outlined earlier here, CAF is an insidious condi-
tion, and there are various stages in its development in
which adhesion molecules may be relevant [26]. SeveralFig. 1. Kaplan–Meyer survival curves for the CAF recipient group
studies have demonstrated that monoclonal antibodydivided according to genotype for ICAM 469. The number at risk in
each group was: (d) 469K 5 26 and (j) 269E 5 28. The log-rank (mAb) strategies aimed at disruption of ICAM-1 func-
statistic is P 5 0.033. tion by blocking the interaction between ICAM-1 and
its receptor (LFA-1) result in immunosuppression [27]
and may also limit ischemic damage [28, 29]. The long-
term effects of the initial adhesion molecule blockadeeffects in either the occurrence or progression of CAF
have been investigated using a soluble ligand of P-selectinwith any of the selectin polymorphisms studied here.
and E-selectin to block interactions postreperfusion inThis may be because the polymorphisms studied are
a rat allograft model of CAF [30]. The results showednot operative in this disease process or, alternatively,
that the blocking of the initial selectin-mediated pro-because the sample sizes were insufficient to detect a
cesses after reperfusion injury, which are presumed todifference. Clearly, this negative finding does not exclude
trigger early cellular events, also reduced late renal dys-a role for these genes or adhesion molecules in the patho-
function and the histological changes associated with it.genesis of CAF.
Anti–ICAM-1 antibodies have also been used to in-Our data suggest that ICAM-1 may be an important
duce tolerance in a mouse cardiac allograft model [31].molecule in the pathophysiology of CAF. There are sev-
However, anti–ICAM-1 was insufficient by itself to in-eral potential mechanisms by which the polymorphisms
duce tolerance and required the coadministration ofin ICAM-1 studied here may have functional effects,
anti–LFA-1. Currently, there are no data from studies ofincluding actions in leukocyte adhesion, leukocyte traf-
anti–ICAM-1 or anti–LFA-1 mAbs to indicate whetherficking, as a minor histocompatibility antigen, or costi-
receptor blocking or activation is the mechanism bymulation, and the development of graft tolerance.
which they exert their functional effects. Neither areThe two polymorphisms studied encode structural
there any published reports of the effect of blocking thechanges in distinct regions of the molecule. The 241 G/R
Mac-1–ICAM-1 interaction, thus leaving the exact rolepolymorphism is in exon 4 and results in a change from
of ICAM-1 in these pathways ill-defined. However,glutamine to arginine in the third immunoglobulin-like
ICAM-1 is clearly central to several of the immunologi-domain of ICAM-1, which is the putative Mac-1 binding
cal processes considered important in the pathogenesissite [21]. Mac-1 (CD11b/CD18) is a b2 integrin, expressed
of CAF.on most leukocytes, that functions as a receptor for
Intercellular adhesion molecule-1 is a cell surface mol-ICAM-1. Mac-1 can also interact with ICAM-1 indirectly
ecule, and the different polymorphic variants could theo-as a result of linkage between the two molecules by
retically act as minor histocompatibility antigens. It isfibrinogen [22]. The precise amino acid motif for Mac-1
unlikely that ICAM-1 variants would be sufficient tobinding is not yet known. However, integrins generally
produce rejection in a system in which they were therecognize short sequences in their ligands containing a
only mismatch, thus fulfilling the strict definition of akey acidic residue essential for receptor binding [23].
minor antigen. However, it is possible that disparity be-Furthermore, it has been shown that single amino acid
tween donor and recipient could affect the qualitativechanges in the third domain of ICAM-1 can result in
nature of a rejection episode. Such an effect does notaugmented binding to Mac-1 in vitro. Thus, polymor-
seem likely given our results, which showed that therephisms in this region may likewise provide a gain of func-
was no pattern of mismatching for ICAM-1 in our recipi-tion in vivo [21]. In addition, normal binding between
an integrin and its ligand results in switching from a low ent–donor pairs, and in addition, the ICAM-1 R241 allele
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C, Feehally J, Furness PN: Early measurement of interstitialwas found at increased frequency in both donors and
fibrosis predicts long-term renal function and graft survival in renal
recipients, again making such an effect unlikely. transplantation. Br J Surg 83:1082–1085, 1996
6. Springer T: Traffic signals on endothelium for lymphocyte recircu-Aside from its primary role in enhancing leukocyte
lation and leucocyte emigration. (abstract) Annu Rev Physioladhesion, ICAM-1 also functions as an accessory mole-
57:827-872, 1995
cule in antigen presentation. This costimulatory activity 7. van Seventer G, Shimuzu Y, Hogan K, Shaw S: The LFA-1
ligand ICAM-1 provides an important costimulatory signal foris critical for the production of optimal T-cell function,
T-cell receptor-mediated activation of resting T cells. J Immunolas demonstrated by the inhibitory effects of antibodies
144:4579–4586, 1990
directed against ICAM-1 in vitro [7]. In the absence 8. Takada M, Chandraker A, Nadeau K, Sayegh M, Tilney N:
The role of the B7 costimulatory pathway in experimental coldof costimulation, the T-cell response is directed toward
ischemia/reperfusion injury. J Clin Invest 100:1199–1203, 1997anergy, which would clearly favor long-term survival in
9. Kasiske B, Kalil R, Lee H, Rao K: Histopathologic findings
the setting of renal transplantation. associated with a chronic, progressive decline in renal allograft
function. Kidney Int 40:514–524, 1991The ICAM R241 variant may affect costimulation in
10. Fuggle S, Sanderson J, Gray D, Richardson A, Morris P: Varia-both the graft, with donor endothelial cells expressing
tion in expression of endothelial adhesion molecules in pretrans-
the variant molecule, and also the recipient lymph nodes, plant and transplanted kidneys: Correlation with intragraft events.
Transplantation 55:117–123, 1993where variant expression on recipient antigen-presenting
11. Brockmeyer C, Ulbrecht M, Schendel D, Weiss E, Hillebrandcells would also provide a mechanism for a gain of func-
G, Burkhardt K, Land W, Gokel MJ, Reithmu¨ller G: Distribu-
tion. A potential effect on costimulation is particularly tion of cell adhesion molecules (ICAM-1, VCAM-1, ELAM-1) in
renal tissue during allograft rejection. Transplantation 55:610-615,likely for the 469E/K polymorphism, as the reduction in
1993graft survival was apparent in only the recipient genotype.
12. Hill P, Main I, Atkins R: ICAM-1 and VCAM-1 in human renal
In conclusion, this study has suggested a possible role allograft rejection. Kidney Int 47:1383–1391, 1995
13. von Willebrand E, Isoniemi J, Hayry P, Paavonen T, Krogerusfor ICAM-1 in the pathogenesis of chronic renal allograft
L: Adhesion molecules and their ligands in chronic rejection offailure in both the incidence and rate of progression of
human renal allografts. Transplant Proc 29:1530–1531, 1997
the disease process. The exact mechanism(s) by which 14. Wenzel K, Ernst M, Rohde K, Baumann G, Speer A: DNA
polymorphisms in adhesion molecule genes: A new risk factor forthese effects are mediated is not clear, but may involve
early atherosclerosis. Hum Genet 97:15–20, 1996several stages of the immune response to an organ allo-
15. Yang H, Vora D, Targan S, Toyada H, Beaudet A, Rotter J:
graft, and thus offers potential for novel interventional Intercellular adhesion molecule 1 gene associations with immuno-
logic subsets of inflammatory bowel disease. Gastroenterologystrategies in the treatment and prevention of CAF. Of
109:440–448, 1995particular importance is the fact that ICAM-1 variants
16. Vora D, Rosenbloom C, Beaudet A, Cottingham R: Polymor-
can be determined pretransplant and may represent a phisms and linkage analysis for ICAM-1 and the selectin gene
cluster. Genomics 21:473–477, 1994predetermined genetic risk factor for late CAF. This
17. Yang H, Vora D, Targan S, Toyoda H, Beaudet AL, Rottertype of information may, in the future, allow therapies
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to be directed toward identified “high-risk” groups. nologic subsets of inflammatory bowel disease. Gastroenterology
109:440–448, 1995
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